Literature DB >> 12358728

Bovine serum albumin enhances nicotinic acetylcholine receptor function in mouse thalamic synaptosomes.

Christopher M Butt1, Scott R Hutton, Michael J Marks, Allan C Collins.   

Abstract

Bovine serum albumin (BSA) enhances nicotinic agonist-induced (86)Rb+ efflux from synaptosomal fractions of the mouse thalamus, but how it does so is not understood. The experiments reported here indicated that BSA enhancement of nicotinic acetylcholine receptor function was rapid, reversible, depended on BSA concentration, and occurred at all points of the nicotinic agonist concentration-response curve. We hypothesized that BSA-extractable compounds, such as long-chain fatty acids, were responsible for inhibiting nicotinic responses in the absence of BSA. The hypothesis was tested by applying arachidonic, linolenic, or oleic acids in the absence of BSA after an initial prewash with BSA. All three fatty acids exhibited a rapid, concentration-dependent inhibition of nicotinic-agonist stimulated ion flux. Concentration-response curves produced after 30 s of pre-treatment with arachidonic acid were similar to those seen when BSA was completely absent. The effects of pre-treatment were reversed immediately by the introduction of BSA. Furthermore, no effects of fatty acids were observed when preparations were continuously exposed to BSA or when BSA was continuously absent. These results suggest that the removal of endogenous, inhibitory compounds is largely responsible for the rapid, potentiating action of BSA at nicotinic acetylcholine receptors expressed in the mouse thalamus.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12358728     DOI: 10.1046/j.1471-4159.2002.01135.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  8 in total

1.  Identification of regions involved in the binding of alpha-bungarotoxin to the human alpha7 neuronal nicotinic acetylcholine receptor using synthetic peptides.

Authors:  Martha Marinou; Socrates J Tzartos
Journal:  Biochem J       Date:  2003-06-01       Impact factor: 3.857

2.  Allosteric modulation of alpha4beta2 nicotinic acetylcholine receptors by HEPES.

Authors:  Maegan M Weltzin; Yanzhou Huang; Marvin K Schulte
Journal:  Eur J Pharmacol       Date:  2012-06-23       Impact factor: 4.432

3.  Pentameric concatenated (alpha4)(2)(beta2)(3) and (alpha4)(3)(beta2)(2) nicotinic acetylcholine receptors: subunit arrangement determines functional expression.

Authors:  A-L Carbone; M Moroni; P-J Groot-Kormelink; I Bermudez
Journal:  Br J Pharmacol       Date:  2009-03       Impact factor: 8.739

Review 4.  Development of novel pharmacotherapeutics for tobacco dependence: progress and future directions.

Authors:  Dympna Harmey; Patrick R Griffin; Paul J Kenny
Journal:  Nicotine Tob Res       Date:  2012-09-27       Impact factor: 4.244

5.  Desformylflustrabromine Modulates α4β2 Neuronal Nicotinic Acetylcholine Receptor High- and Low-Sensitivity Isoforms at Allosteric Clefts Containing the β2 Subunit.

Authors:  Maegan M Weltzin; Marvin K Schulte
Journal:  J Pharmacol Exp Ther       Date:  2015-05-29       Impact factor: 4.030

6.  Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors.

Authors:  Miriam Melis; Giuliano Pillolla; Antonio Luchicchi; Anna Lisa Muntoni; Sevil Yasar; Steven R Goldberg; Marco Pistis
Journal:  J Neurosci       Date:  2008-12-17       Impact factor: 6.167

7.  Non-agonist-binding subunit interfaces confer distinct functional signatures to the alternate stoichiometries of the alpha4beta2 nicotinic receptor: an alpha4-alpha4 interface is required for Zn2+ potentiation.

Authors:  Mirko Moroni; Ranjit Vijayan; Anna Carbone; Ruud Zwart; Philip C Biggin; Isabel Bermudez
Journal:  J Neurosci       Date:  2008-07-02       Impact factor: 6.167

8.  Characterizing low affinity epibatidine binding to α4β2 nicotinic acetylcholine receptors with ligand depletion and nonspecific binding.

Authors:  Alexandra M Person; Gregg B Wells
Journal:  BMC Biophys       Date:  2011-11-23       Impact factor: 4.778

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.